Phase I/II study of temozolomide and Gleevec (imatinib mesylate [imatinib], formerly known as STI571) in advanced melanoma
Phase of Trial: Phase I/II
Latest Information Update: 06 Sep 2018
At a glance
- Drugs Imatinib (Primary) ; Temozolomide (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 28 Aug 2018 Status changed from active, no longer recruiting to completed.
- 23 Sep 2016 Status changed from completed to active, no longer recruiting.
- 02 Dec 2011 Actual end date (March 2011) added as reported by ClinicalTrials.gov.